Sinopharm takes control of Shandong Pharmaceutical Glass via USD 482.5m placement

Shandong Pharmaceutical Glass has filed with the Shanghai Stock Exchange to issue up to 199m new A-shares and raise up to USD 482.5m (CNY 3.235bn), with proceeds earmarked entirely for working capital. The placement hands control of the pharmaceutical glass maker to Sinopharm International, part of state-owned China National Pharmaceutical Group, replacing former controlling shareholder Luzhong Investment and the Yiyuan county finance bureau. The exchange accepted the filing on 17 September 2026; CSRC registration is still pending.

Why this mattersA central state conglomerate taking control of China's leading pharma glass maker could reshape supply terms and consolidation in the domestic pharmaceutical packaging chain.

• Shandong Pharmaceutical Glass (600529.SH) plans to issue up to 199m new A-shares to raise up to USD 482.5m (CNY 3.235bn), entirely for working capital
• Sinopharm International replaces Luzhong Investment and the Yiyuan county finance bureau as controlling shareholder, with the State Council's SASAC as ultimate controller
• The Shanghai Stock Exchange accepted the placement filing on 17 September 2026; CSRC registration is still pending
• The two cash subscribers are China International Medicine and Health Co and Shandong Yaoxin Health Industry Co
• 2025 revenue fell 8.78% to USD 667m (CNY 4.474bn) and net profit fell 26.87% to USD 103m (CNY 690m), under centralised drug procurement pricing
• Inventory rose to USD 259m (CNY 1.734bn) at end-June 2026 from USD 191m (CNY 1.279bn) at end-2024

Relevant to you? Yes No